<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - TIBOLONE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>TIBOLONE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Short-term treatment of symptoms of oestrogen deficiency (including women being treated with gonadotrophin releasing hormone analogues)</span>,
                <span class="indication">Osteoporosis prophylaxis in women at high risk of fractures when other prophylaxis contra-indicated or not tolerated</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                2.5 mg daily.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Avoid; toxicity in <i>animal</i> studies.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Avoid in acute liver disease or if history of liver disease and liver function tests not returned to normal.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li><xref format="dita" href="#PHP78608" type="bookmark" namespace="/treatment-summaries/acute-porphyrias">Acute porphyrias</xref></li>
            <li>active or recent arterial thromboembolic disease (e.g. angina or myocardial infarction)</li>
            <li>active thrombophlebitis</li>
            <li>Dubin-Johnson and Rotor syndrome (or monitor closely)</li>
            <li>history of breast cancer</li>
            <li>history of cardiovascular disease</li>
            <li>history of cerebrovascular disease</li>
            <li>history of recurrent venous thromboembolism (unless already on anticoagulant treatment)</li>
            <li>history of thromboembolism</li>
            <li>history of thrombophlebitis</li>
            <li>hormone-dependent tumours</li>
            <li>liver disease (where liver function tests have failed to return to normal)</li>
            <li>oestrogen-dependent cancer</li>
            <li>thrombophilic disorder</li>
            <li>uninvestigated or undiagnosed vaginal bleeding</li>
            <li>untreated endometrial hyperplasia</li>
            <li>venous thromboembolism</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Abdominal pain, facial hair, leucorrhoea, vaginal bleeding, weight changes,
              </p>
              <p>
                <strong>rare:</strong> Amnesia,
              </p>
              <p>
                <strong>notKnown:</strong> Arthralgia, breast cancer, depression, dizziness, gastro-intestinal disturbances, headache, increased risk of gall-bladder disease, migraine, myalgia, oedema, pruritus, rash, seborrhoeic dermatitis, symptoms of endometriosis may be exacerbated, uterine fibroids may increase in size, visual disturbances,
              </p>
        
        
            <section class="advice">
                <h3>Vaginal bleeding</h3>
              <p>Investigate for endometrial cancer if bleeding continues beyond 6 months or after stopping treatment.</p>
            </section>
            <section class="advice">
                <h3>Reasons to withdraw treatment</h3>
              <p>Withdraw treatment if signs of thromboembolic disease, abnormal liver function tests, or signs of cholestatic jaundice.</p>
            </section>
        
      </section>





      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            <xref format="dita" href="#PHP78608" type="bookmark" namespace="/treatment-summaries/acute-porphyrias">Acute porphyrias</xref>
          </li>
          <li>
            diabetes (increased risk of heart disease)
          </li>
          <li>
            epilepsy
          </li>
          <li>
            factors predisposing to thromboembolism
          </li>
          <li>
            history of breast nodules&#8212;closely monitor breast status (risk of breast cancer)
          </li>
          <li>
            history of endometrial hyperplasia
          </li>
          <li>
            history of fibrocystic disease&#8212;closely monitor breast status (risk of breast cancer)
          </li>
          <li>
            history of liver disease
          </li>
          <li>
            hypertriglyceridaemia
          </li>
          <li>
            hypophyseal tumours
          </li>
          <li>
            migraine (or migraine-like headaches)
          </li>
          <li>
            presence of antiphospholipid antibodies (increased risk of thrombotic events)
          </li>
          <li>
            prolonged exposure to unopposed oestrogens may increase risk of developing endometrial cancer
          </li>
          <li>
            risk factors for oestrogen-dependent tumours (e.g. breast cancer in first-degree relative)
          </li>
          <li>
            risk of stroke
          </li>
        </ul>
        <ul>
          <li>
            <p>The product literature advises caution in other conditions including hypertension, renal disease, asthma, epilepsy, sickle-cell disease, melanoma, otosclerosis, multiple sclerosis, and systemic lupus erythematosus (but care required if antiphospholipid antibodies present). Evidence for caution in these conditions is unsatisfactory and many women with these conditions may stand to benefit from HRT.</p>
          </li>
        </ul>
      </section>




      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>Unsuitable for use in the premenopause (unless being treated with gonadotrophin-releasing hormone analogue) and as (or with) an oral contraceptive.</p><p>Also unsuitable for use within 12 months of last menstrual period (may cause irregular bleeding).</p><p>If transferring from cyclical HRT, start at end of regimen; if transferring from continuous-combined HRT, start at any time.</p>
            </section>
      </section>









      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of TIBOLONE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP75529"><a href="../medicinalForm/PHP75529.html" data-target="#PHP75529" data-action="load">Tablet</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
